Inflammatory Bowel Disease Enrollment Form
Medications A (Avsola)

CVS specialty®

Fax Referral To: 1-877-232-5455
Address: 500 Ala Moana Blvd., Ste 1-A Honolulu, HI 96813

Phone: 1-800-896-1464

Six Simple Steps to Submitting a Referral

1 PATIENT INFORMATION *(Complete or include demographic sheet)*

Patient Name: _____ DOB: _____
Address: _____City, State, ZIP Code: _____
Gender: ☐ Male ☐ Female
Preferred Contact Methods: ☐ Phone (to primary # provided below) ☐ Text (to cell # provided below) ☐ Email (to email provided below)
Note: Carrier charges may apply. If unable to contact via text or email, Specialty Pharmacy will attempt to contact by phone.
Primary Phone: _____ Alternate Phone: _____
If **Minor**, Parent/Caregiver/Guardian Name (Last, First): _____
Relationship to minor: _____
Email: _____ Last Four of SSN: _____ Primary Language: _____

2 PRESCRIBER INFORMATION

Prescriber's Name: _____ State License #: _____
NPI #: _____ DEA #: _____ Group or Hospital: _____
Address: _____ City, State, ZIP Code: _____
Phone: _____ Fax_____ Contact Person: _____ Contact's Phone: _____

3 INSURANCE INFORMATION Please fax copy of prescription and insurance cards with this form, if available (front and back)

4 DIAGNOSIS AND CLINICAL INFORMATION

Needs by Date:_____ Ship to: ☐ Patient ☐ Office ☐ Other:_____

Diagnosis (ICD-10):

☐ K50.00 Crohn's Disease of Small Intestine Without Complications ☐ K50.10 Crohn's Disease of Large Intestine Without Complications
☐ K50.80 Crohn's Disease of Small & Large Intestine Without Complications
☐ K50.90 Crohn's Disease, Unspecified, Without Complications ☐ K51.00 Ulcerative (chronic) pancolitis without complications
☐ K51.30 Ulcerative (chronic) rectosigmoiditis without complications ☐ K51.50 Left sided colitis without complications
☐ K51.90 Ulcerative colitis, unspecified, without complications ☐ Other Code: _____ Description _____

Patient Clinical Information:

Allergies: _____ Weight: _____lb/kg Height: _____in/cm
TB Test Result: _____ Date: _____ Hepatitis status: _____
First time receiving IBD Therapy? ☐ Yes ☐ No
If No, previous product used: _____ Last dose given: _____ Next dose due: _____

Nursing:

Specialty pharmacy to coordinate injection training/ home health infusion nurse visit necessary ☐ Yes ☐ No
Site of Care: ☐ MD office ☐ Infusion Clinic ☐ Outpatient Health ☐ Home Health
Injection training not necessary. Date training occurred: _____
Reason: ☐ MD office training patient ☐ Pt already independent ☐ Referred by MD to alternate trainer
Prescriber Phone:_____

5 PRESCRIPTION INFORMATION

MEDICATION	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
☐ Avsola	100 mg vial	☐ Crohn's Disease (Adult and Pediatric ≥6 years old) Induction Dose: Infuse IV at 5 mg/kg (Dose = _____mg) at weeks 0, 2, 6 and every 8 weeks thereafter ☐ Crohn's Disease (Adult) Maintenance Dose: Infuse IV at 5-10 mg/kg (Dose = _____mg) every 8 weeks ☐ Crohn's Disease (Pediatric ≥6 years old) Maintenance Dose: Infuse IV at 5 mg/kg (Dose = _____mg) every 8 weeks ☐ Ulcerative Colitis (Adult and Pediatric ≥6 years old) Induction Dose: Infuse IV at 5 mg/kg (Dose = _____mg) at weeks 0, 2, 6 and every 8 weeks thereafter ☐ Ulcerative Colitis (Adult and Pediatric ≥6 years old) Maintenance Dose: Infuse IV at 5 mg/kg (Dose = _____mg) every 8 weeks ☐ Other: _____	Quantity: _____ # of 100 mg vial(s) Refills: _____

☐ Patient is interested in patient support programs **STAMP SIGNATURE NOT ALLOWED** Ancillary supplies and kits provided as needed for administration

6 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute **Prescriber's Signature:** _____**Date:** _____	May Substitute / Product Selection Permitted / Substitution Permissible **Prescriber's Signature:** _____**Date:** _____

CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "**No Substitution**" _____ **ATTN: New York and Iowa providers,** please submit electronic prescription

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

Inflammatory Bowel Disease Enrollment Form
Medications C-H (Cimzia, Entyvio, Humira)

Please Complete Patient and Prescriber Information

Patient Name: _____ Patient DOB: _____
Prescriber Name: _____ Prescriber Phone: _____

Patient Clinical Information:

Allergies: _____ Weight: _____ lb/kg Height: _____ In/cm
TB Test Result: _____ Date: _____

5 PRESCRIPTION INFORMATION

MEDICATION	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
☐ Cimzia	Cimzia Starter Kit (6 prefilled syringes)	Induction Dose: Inject SC 400 mg (2 injections) on day 1, and at weeks 2 and 4. If response occurs, follow with 400 mg every four weeks ☐ Other: _____	Quantity: 1 kit (6 prefilled syringes) Refills: 0
☐ Cimzia	☐ 200 mg/1 mL prefilled syringe ☐ 200 mg vial	Maintenance Dose: Inject SC 400 mg (2 injections) every 4 weeks ☐ Other: _____	Quantity: _____ Refills: _____
☐ Entyvio	300 mg in a single dose vial in individual carton	☐ Induction Dose: 300 mg infused IV over 30 minutes at 0, 2 and 6 weeks, then every 8 weeks thereafter ☐ Maintenance Dose: 300 mg infused IV over 30 minutes every 8 weeks ☐ Other: _____	Quantity: _____ Refills: _____
☐ Humira	Adult Crohn's Disease/Ulcerative Colitis: PEN HUMIRA Starter Pack (CF) 80 mg/0.8 mL	Initial Dose: ☐ Inject SC 160 mg on Day 1, 80 mg on Day 15, then continue with maintenance dose starting Day 29 ☐ Inject SC 80 mg on Day 1, 80 mg on Day 2, 80 mg on Day 15, then continue with maintenance dose starting Day 29 ☐ Other: _____	Quantity: 1 kit (3 pens) Refills: 0
☐ Humira	Adult Crohn's Disease/Ulcerative Colitis: ☐ PEN HUMIRA (CF) 40 mg/0.4 mL ☐ SYRINGE HUMIRA (CF) 40 mg/0.4 mL ☐ PEN HUMIRA 40 mg/0.8 mL ☐ SYRINGE HUMIRA 40 mg/0.8 mL	Maintenance Dose: ☐ Inject SC 40 mg every other week ☐ Other: _____	Quantity: ☐ #2 (1 month) ☐ #6 (3 month) Refills: _____
☐ Humira	**17 kg (37 lbs) to less than 40 kg (88 lbs); ≥ 6 years:** SYRINGE HUMIRA Starter Pack (CF) 80 mg/0.8 mL, 40 mg/0.4 mL	Pediatric Crohn's Disease Initial Dose: ☐ Inject SC 80 mg Day 1, then 40 mg Day 15, then continue with maintenance dose starting Day 29 ☐ Other: _____	Quantity: 1 kit (2 syringes) Refills: 0
☐ Humira	**40 kg (88 lbs) and greater; ≥ 6 years:** ☐ PEN HUMIRA Starter Pack (CF) 80 mg/0.8 ml ☐ SYRINGE HUMIRA Starter Pack (CF) 80 mg/0.8 mL ☐ PEN HUMIRA Starter Pack 40 mg/0.8 mL ☐ SYRINGE HUMIRA Starter Pack 40 mg/0.8 mL	Pediatric Crohn's Disease Initial Dose: ☐ Inject SC 160 mg Day 1, then 80 mg Day 15, then continue with maintenance dose starting Day 29 ☐ Inject SC 80 mg Day 1, 80 mg Day 2, 80 mg Day 15, then continue with maintenance dose starting Day 29 ☐ Other: _____	Quantity: QS Refills: 0
☐ Humira	**17 kg (37 lbs) to less than 40 kg (88 lbs); ≥ 6 years:** SYRINGE HUMIRA (CF) 20 mg/0.2 mL	Pediatric Crohn's Disease Maintenance Dose: ☐ Inject SC 20 mg every other week ☐ Other: _____	Quantity: ☐ #2 (1 month) ☐ #6 (3 month) Refills: _____

☐ Patient is interested in patient support programs **STAMP SIGNATURE NOT ALLOWED** Ancillary supplies and kits provided as needed for administration

6 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute **Prescriber's Signature: _____ Date: _____**	May Substitute / Product Selection Permitted / Substitution Permissible **Prescriber's Signature: _____ Date: _____**

CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "**No Substitution**" _____ **ATTN: New York and Iowa providers,** please submit electronic prescription

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

Inflammatory Bowel Disease Enrollment Form

Medications H-R (Humira, Inflectra, Infliximab, Remicade, Renflexis)

Please Complete Patient and Prescriber Information

Patient Name: _____ Patient DOB: _____

Prescriber Name: _____ Prescriber Phone: _____

Patient Clinical Information:

Allergies: _____ Weight: _____ lb/kg Height: _____ In/cm

TB Test Result: _____ Date: _____

5 PRESCRIPTION INFORMATION

MEDICATION	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
☐ Humira	**40 kg (88 lbs) and greater; ≥ 6 years:** ☐ PEN HUMIRA (CF) 40 mg/0.4 mL ☐ SYRINGE HUMIRA (CF) 40 mg/0.4 mL ☐ PEN HUMIRA 40 mg/0.8 mL ☐ SYRINGE HUMIRA 40 mg/0.8 mL	Pediatric Crohn's Disease Maintenance Dose: ☐ Inject SC 40 mg every other week ☐ Other: _____	Quantity: ☐ #2 (1 month) ☐ #6 (3 month) Refills: _____
☐ Humira	**20 kg (44 lbs) to less than 40 kg (88 lbs); ≥ 5 years:** ☐ PEN HUMIRA (CF) 40 mg/0.4 mL ☐ SYRINGE HUMIRA (CF) 40 mg/0.4 mL	Pediatric Ulcerative Colitis Initial Dose: ☐ Inject SC 80 mg Day 1, 40 mg weekly (Day 8 and Day 15), then continue with maintenance dose starting Day 29 ☐ Other: _____	Quantity: 4 Pens/4 Prefilled syringes Refills: 0
☐ Humira	**20 kg (44 lbs) to less than 40 kg (88 lbs); ≥ 5 years:** ☐ PEN HUMIRA (CF) 40 mg/0.4 mL ☐ PEN HUMIRA (CF) 40 mg/0.4 mL ☐ SYRINGE HUMIRA (CF) 20 mg/0.2 mL	Pediatric Ulcerative Colitis Maintenance Dose: ☐ Inject SC 20 mg every week ☐ Inject SC 40 mg every other week ☐ Other: _____	Quantity: ☐ 1-month supply ☐ 3-month supply Refills: _____
☐ Humira	**40 kg (88 lbs) and greater; ≥ 5 years:** ☐ PEN HUMIRA (CF) 80 mg/0.8 mL ☐ PEN HUMIRA (CF) 40 mg/0.4 mL ☐ SYRINGE HUMIRA (CF) 40 mg/0.4 mL	Pediatric Ulcerative Colitis Maintenance Dose: ☐ Inject SC 40 mg every week ☐ Inject SC 80 mg every other week ☐ Other: _____	Quantity: ☐ 1-month supply ☐ 3-month supply Refills: _____
☐ Inflectra ☐ Infliximab ☐ Remicade ☐ Renflexis	100 mg vial	☐ Crohn's Disease (Adult and Pediatric ≥6 years old) Induction Dose: Infuse IV at 5 mg/kg (Dose = _____mg) at weeks 0, 2, 6 and every 8 weeks thereafter ☐ Crohn's Disease (Adult) Maintenance Dose: Infuse IV at 5-10 mg/kg (Dose = _____mg) every 8 weeks ☐ Crohn's Disease (Pediatric ≥6 years old) Maintenance Dose: Infuse IV at 5 mg/kg (Dose = _____mg) every 8 weeks ☐ Ulcerative Colitis (Adult and Pediatric ≥6 years old) Induction Dose: Infuse IV at 5 mg/kg (Dose = _____mg) at weeks 0, 2, 6 and every 8 weeks thereafter ☐ Ulcerative Colitis (Adult and Pediatric ≥6 years old) Maintenance Dose: Infuse IV at 5 mg/kg (Dose = _____mg) every 8 weeks ☐ Other: _____	Quantity: _____ # of 100 mg vial(s) Refills: _____

☐ Patient is interested in patient support programs **STAMP SIGNATURE NOT ALLOWED** Ancillary supplies and kits provided as needed for administration

6 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute **Prescriber's Signature: _____ Date: _____**	May Substitute / Product Selection Permitted / Substitution Permissible **Prescriber's Signature: _____ Date: _____**

CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "**No Substitution**" _____ **ATTN: New York and Iowa providers,** please submit electronic prescription

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

Inflammatory Bowel Disease Enrollment Form

Medications R-Z (Rinvoq, Simponi, Stelara, Tysabri, Xeljanz, Zeposia)

Please Complete Patient and Prescriber Information

Patient Name: _____ Patient DOB: _____

Prescriber Name: _____ Prescriber Phone: _____

Patient Clinical Information:

Allergies: _____ Weight: _____ lb/kg Height: _____ In/cm

TB Test Result: _____ Date: _____

5 PRESCRIPTION INFORMATION

MEDICATION	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
☐ Rinvoq	45 mg	Induction Dose: ☐ Take 1 tablet once daily for 8 weeks ☐ Other: _____	Quantity: 1 btl = 28 Refill: 1
☐ Rinvoq	☐ 15 mg ☐ 30 mg	Maintenance Dose: ☐ Take 1 tablet once daily ☐ Other: _____	Quantity: _____ Refills: _____
☐ Simponi	☐ 100 mg/mL in a single-dose prefilled SmartJect autoinjector ☐ 100 mg/mL in a single-dose prefilled syringe	☐ Induction Dose: Inject SC 200 mg initially (given as 2 subcutaneous injections of 100 mg each) at Week 0, followed by 100 mg at Week 2 and then 100 mg every 4 weeks ☐ Maintenance Dose: Inject SC 100 mg every 4 weeks ☐ Other: _____	Quantity: _____ Refills: _____
☐ Stelara	130 mg/26 mL (5 mg/mL) IV single-dose vial Date Infusion was completed or scheduled: _____. (This date is needed to determine shipment of Stelara SC maintenance dosage)	Single IV Induction Dose: ☐ 55 kg or less 260 mg at Week 0: # of vials to be used 2 ☐ more than 55 kg to 85 kg 390 mg at Week 0: # of vials to be used 3 ☐ more than 85 kg 520 mg at Week 0: # of vials to be used 4 ☐ Other: _____	Quantity: ☐ 2 Vials ☐ 3 Vials ☐ 4 Vials Refills: 0
☐ Stelara	90 mg/mL SC dose in a single-dose prefilled syringe	☐ 90 mg SC dose 8 weeks after the initial IV induction dose, then every 8 weeks thereafter ☐ Other: _____	Quantity: _____ Refills: _____
☐ Tysabri	NA	Please complete a MS TOUCH/Tysabri enrollment form and indicate CVS/specialty as your preferred pharmacy provider. (For questions, please contact TOUCH Prescribing Program at 1-800-456-2255)	Quantity: 0 Refills: 0
☐ Xeljanz	☐ 5 mg ☐ 10 mg	☐ 10 mg twice daily for at least 8 weeks; followed by 5 or 10 mg twice daily, depending on therapeutic response. Use the lowest effective dose to maintain response. Discontinue Xeljanz after 16 weeks of treatment with 10 mg twice daily if adequate therapeutic benefit is not achieved. ☐ Other: _____	Quantity: _____ Refills: _____
☐ Zeposia	Starter Kit (4 capsules of 0.23 mg, 3 capsules of 0.46 mg and one bottle containing 30 capsules of 0.92 mg)	☐ Take 0.23 mg capsule once daily on days 1-4, followed by 0.46 mg capsule once daily on days 5-7, then take 0.92 mg capsule once daily starting on day 8)	Quantity: 37-day supply Refill: 0
☐ Zeposia	7-Day Starter Pack (4 capsules of 0.23 mg and 3 capsules of 0.46 mg)	☐ Take 0.23 mg capsule once daily on days 1-4, followed by 0.46 mg capsule once daily on days 5-7	Quantity: 7-day supply Refill: 0
☐ Zeposia	0.92 mg capsules	☐ Take 0.92 mg capsule once daily ☐ Other: _____	Quantity: _____ Refills: _____

☐ Patient is interested in patient support programs **STAMP SIGNATURE NOT ALLOWED** Ancillary supplies and kits provided as needed for administration

6 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute **Prescriber's Signature: _____ Date: _____**	May Substitute / Product Selection Permitted / Substitution Permissible **Prescriber's Signature: _____ Date: _____**

CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "**No Substitution**" _____ **ATTN: New York and Iowa providers,** please submit electronic prescription

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

Inflammatory Bowel Disease Enrollment Form
Nursing Medications

Please Complete Patient and Prescriber Information

Patient Name: _____ Patient DOB: _____
Prescriber Name: _____ Prescriber Phone: _____

Patient Clinical Information:

Allergies: _____Weight: _____lb/kg Height:_____In/cm
TB Test Result:_____ Date:_____

5 PRESCRIPTION INFORMATION

Complete Items below, required for Home Infusion/Coram AIS:

MEDICATION/SUPPLIES	ROUTE	DOSE/STRENGTH/DIRECTIONS	QUANTITY/REFILLS
Catheter ☐ PIV ☐ PORT ☐ PICC	IV	Catheter Care/Flush – Only on drug admin days – SASH or PRN to maintain IV access and patency PIV – NS 5 mL (Heparin 10 units/mL 3-5 mL if multiple days) PORT/PICC – NS 10 mL & Heparin 100 units/mL 3-5 mL, and/or 10 mL sterile saline to access port a cath	Quantity: _____ Refills: _____
Hydration: NS D5W	IV	Pre: 500 mL 1000 mL Other: _____ Concurrent: 500 mL 1000 mL Other: _____ (Not to be infused using the same access as Ig) Post: 500 mL 1000 mL Other: _____	Hydration max infusion rate _____ mL/hr (Adult max rate 250 mL/hr unless otherwise indicated)
☐ Epinephrine **nursing requires**	☐ IM ☐ SC	☐ Adult 1:1000, 0.3 mL (>30 kg/>66 lbs) ☐ Peds 1:2000, 0.3 mL (15-30 kg/33-66 lbs) ☐ Infant 0.1 mL/0.1 mL, 0.1 mL (7.5-15 kg/16.5-33 lbs) PRN severe allergic reaction – Call 911 May repeat in 5-15 minutes as needed	Quantity: _____ Refills: _____
☐ Diphenhydramine Oral	PO	☐ Premedication ☐ 12.25 mg/kg (0-30 kg) ☐ 25 mg ☐ 50 mg (Over 30 kg) PRN severe allergic reaction – Call 911	Quantity: _____ Refills: _____
☐ Diphenhydramine 50 mg/mL vial	☐ Slow IV ☐ IM	☐ 1 mg/kg (under 15 kg) ☐ 12.5-50 mg (15-30 kg) ☐ 25 mg ☐ 50 mg (Over 30 kg) PRN severe allergic reaction – Call 911 May repeat in 3-5 minutes as needed (Max dose-50 mg)	Quantity: _____ Refills: _____
☐ Flush Orders	☐ Peripheral Access ☐ Central Venus Access	☐ 20 mL NS post flush ☐ 30 mL NS post flush ☐ 40 mL NS post flush ☐ 50 mL NS post flush ☐ _____	Send quantity sufficient for medication days supply
Additional Medication: _____	_____	_____	_____

☐ Patient is interested in patient support programs **STAMP SIGNATURE NOT ALLOWED** Ancillary supplies and kits provided as needed for administration

6 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute **Prescriber's Signature: _____Date: _____**	May Substitute / Product Selection Permitted / Substitution Permissible **Prescriber's Signature: _____Date: _____**

CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "**No Substitution**" _____ **ATTN: New York and Iowa providers,** please submit electronic prescription

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.